Stockwinners Market Radar for July 05, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT Biogen says FDA accepts BLA for lecanemab under accelerated approval pathway - Eisai (ESALY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration has accepted the Biologics License Application, or BLA, under the accelerated approval pathway for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD with confirmed presence of amyloid pathology in the brain. Eisai's application, which was completed in early May 2022, has been granted Priority Review, with a Prescription Drug User Fee Act, or PDUFA, action date of January 6, 2023. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and Eisai completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the Fall of 2022. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Eisai utilized the FDA's Accelerated Approval Pathway in an effort to streamline the submission process for the potential traditional approval of lecanemab in order to expedite patients' access to lecanemab. Dependent upon the results of the Clarity AD clinical trial, Eisai will submit for traditional approval of lecanemab to the FDA during Eisai's fiscal year 2022, which ends on March 31, 2023. Haruo Naito, Chief Executive Officer at Eisai, said, "The acceptance of lecanemab's BLA with priority review is an important milestone in serving people living with Alzheimer's disease who have been waiting for new treatment options to address an underlying pathology of Alzheimer's disease. We will continue to actively cooperate with the FDA's review in an effort to bring this new treatment option to people living with Alzheimer's disease and their families as soon as possible."

18:22 EDT SilverBow Resources raises FY22 production view to 272-282 from 235-255 MMCFE/D - SilverBow also estimates its Q2 average daily production to be 236 to 238 million cubic feet of gas equivalent, MMcfe/d with about 78% gas, which includes 51 days of production from the SandPoint assets. SilverBow expects to exit December producing approximately 350 MMcfe/d, which represents a 25% increase compared to the Company's average daily production for the month of June. The company states that it has "closed its previously announced acquisition of substantially all of the oil and gas assets from Sundance Energy, Inc. and certain affiliated entities. Total purchase consideration due to Sundance, subject to customary closing adjustments, was comprised of approximately $225 million in cash and 4.1 million shares of SilverBow's common stock. The cash portion of the purchase was funded with cash on hand and borrowings under the Company's revolving credit facility. Further, SilverBow updated its outlook to adjust for the recent closings of both the Sundance acquisition and the acquisition of the assets of the oil and gas assets of SandPoint Operating, LLC, a subsidiary of SandPoint Resources, LLC, on May 10, 2022. Additionally, the Company has provided its oil and gas hedged volumes as of the end of the second quarter of 2022." CEO Sean Woolverton says: "The successful closing of this acquisition provides a step-change to SilverBow's production base, drilling inventory and cash flow profile. Our June production rate is set to increase by over 25% to over 58,000 Boe/d by year-end, driven by the combination of acquired production and the increase to our capital program by adding a second rig. Our multi-year growth profile is significant, as we estimate we will grow annual production 30% or more in both 2022 and 2023. Our increased scale is supported by over 600 high-return locations, providing over a decade of drilling inventory at a two-rig pace and operating cash flows that fund our development plan at a re-investment rate of approximately 60%."

18:06 EDT Lockheed Martin awarded $185.92M Navy contract modification - Lockheed Martin was awarded a $185.92M cost-plus-incentive-fee contract modification to previously awarded contract to exercise an option for engineering design and development. Work is expected to be completed by September 2023. FY22 research, development, test and evaluation funds in the amount of $17.83M and FY22 shipbuilding and conversion funds in the amount of $535,657 will be obligated at the time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:25 EDT Xometry CEO sells 20K shares of common stock - In a regulatory filing, Xometry disclosed that its CEO Randolph Altschuler sold 20K shares of common stock on July 1st in a total transaction size of $659.2K.

17:06 EDT Vornado completes sale of Center Building in Long Island City, NY for $172.8M - Vornado Realty Trust announced that it has completed the previously announced sale of the Center Building, an eight-story 498,000 square foot office building located at 33-00 Northern Boulevard in Long Island City, New York, for $172.8M. The financial statement gain, which will be recognized in the second quarter, is estimated to be $15M. The tax gain is estimated to be $74M.

17:00 EDT Stride joins S&P SmallCap 600 - Stride was added to the S&P SmallCap 600 index, effective prior to the opening of trading today, Tuesday, July 5, 2022. The S&P SmallCap 600 provides investors with a benchmark for small-sized companies in the U.S. equities market. The 600 companies in the index are selected by Standard & Poor's U.S. Index Committee based on several factors, including financial performance and market capitalization.

16:49 EDT Verrica Pharmaceuticals director buys $10M in common stock - In a regulatory filing, Verrica Pharmaceuticals disclosed that its director Paul Manning bought 4.8M shares of common stock on July 5th in a total transaction size of $10M.

16:42 EDT Oil States names Philip Moses as COO - On July 1, 2022, the Board of Directors of Oil States International appointed Philip S. Moses as the company's Executive Vice President and Chief Operating Officer, effective immediately. Mr. Moses joined the Company in August 1996. Since May 2021 he has served as the Company's Executive Vice President, Offshore/Manufactured Products and Downhole Technologies.

16:31 EDT Gladstone Commercial sells Jupiter, FL office building - Gladstone Commercial "announced that it sold its Jupiter, FL office building on July 1, 2022. The 60,000 SF building was leased to a single tenant with a lease expiration date of March 10, 2023. Gladstone Commercial realized gross proceeds of $19.0 million and a gain on carrying value of approximately $8.1 million, resulting in a leveraged internal rate of return of approximately 18%. Gladstone Commercial bought the building in 2012 for $15.5 million with a 10+ year lease in place to the single tenant."

16:21 EDT Becton Dickinson names Rishi Grover as chief integrated supply chain officer - Becton Dickinson announced that Rishi Grover has been named executive vice president or EVP, and chief integrated supply chain officer for BD, effective July 7. In this role, Grover will have global responsibility for the leadership of the supply chain, operations, procurement, sustainability, and environmental, health and safety, or EHS, teams across the company and will become a member of the BD executive leadership team.

16:20 EDT Kornit Digital falls 20% to $24.99 after below-consensus Q2 revenue outlook

16:18 EDT Evolution Petroleum CEO Jason Brown to leave company - Evolution Petroleum announced that its President and Chief Executive Officer, Jason Brown, is departing the company in order to pursue other opportunities. The Board of Directors has elected Kelly Loyd, a current member of the Board of Directors, as interim Chief Executive Officer and will immediately initiate a search effort. Robert Herlin, Chairman of the Board of Directors, commented "Jason was brought on board three years ago to substantially increase the Company's scale and asset diversity. To that end, he has been very successful with the completion of four significant acquisitions completed prior to the substantial run-up in commodity prices over the last nine months: two natural gas and gas liquids-focused acquisitions in the Barnett and Jonah Fields and two oil-focused acquisitions in the Williston Basin and Hamilton Dome. In addition to low-decline producing reserves, the acquisitions brought an inventory of accretive development drilling locations that should have a positive impact on Evolution for years to come. We are appreciative of his contributions to the Company, particularly through the pandemic, and wish him well in his new endeavor."

16:16 EDT Leidos appoints Thomas Sanglier as chief audit executive - Leidos (LDOS) announced the appointment of Thomas Sanglier as the company's new chief audit executive. In this role, Sanglier will oversee the company's internal audit function and deliver assessments and assurance. Sanglier brings more than 32 years of experience in the areas of financial and operational auditing, risk assessment, and internal control. He most recently served as Senior Director, Finance & Operations Internal Audit at Raytheon Technologies (RTX).

16:08 EDT STAG Industrial appoints William Crooker as CEO - STAG Industrial announced that, pursuant to its previously announced management succession plan, effective July 1st the Board of Directors appointed William R. Crooker to the role of CEO, in addition to his current role as President, and further appointed Crooker to the Board. As CEO, Crooker will lead and manage the Company's business, execute the strategies developed by management and the Board and serve as the chief spokesperson to the Company's employees, stockholders and business counterparties. dditionally, Benjamin S. Butcher transitioned from CEO to Executive Chairman of the Board. As Executive Chairman, Butcher will manage the business of the Board, regularly consult with Crooker on key corporate matters and serve as a liaison between the Board and the management team. The Company further announced that effective July 1st the Board promoted Michael C. Chase to Executive Vice President, in addition to his current role as Chief Investment Officer. Chase has served as a Senior Vice President - Acquisitions since the Company's formation and initial public offering in 2011 and has been Chief Investment Officer since 2020.

16:07 EDT Aviat Networks completes Redline transaction - Aviat Networks "announced the completion of the acquisition of Redline by a subsidiary of Aviat pursuant to a statutory plan of arrangement under the Canada Business Corporations Act , which now enables Aviat to offer its customers an integrated end-to-end offering for wireless access and transport. Aviat will include Redline in its FY23 guidance which will be provided in the next earnings call. Redline was not part of Aviat during FY22 and will not be included in Aviat's forthcoming FY22 Q4 results. For clarity, Aviat would like to reaffirm its previous FY22 guidance of $296M-$300M in revenue and $37-$39 million in Adjusted EBITDA. Under the terms of the Arrangement, all of the issued and outstanding Common Shares were acquired by Aviat in exchange for consideration of CAD$0.90 per Common Share in an all-cash transaction."

15:58 EDT EPA orders ContextLogic to stop selling several unregistered disinfectants - The U.S. Environmental Protection Agency, or EPA, has ordered ContextLogic to stop selling several unregistered disinfectants through their e-commerce marketplace. The products are unregistered disinfectants being sold in violation of the Federal Insecticide, Fungicide, and Rodenticide Act, or FIFRA. Such practices have been particularly problematic during the COVID-19 pandemic, and EPA will continue to take enforcement actions such as this 'Stop Sale' order to protect public health. EPA has issued the 'Stop Sale' order to prevent the company, located in San Francisco, from continuing to distribute or offer for sale these unregistered disinfectants. The products have been available for sale on the Wish e-commerce marketplace and specifically make problematic claims of effectiveness against viruses, bacteria, and germs. One type of product sold by Wish under various names, including "air sterilization cards" and "degerming cards," claims to be a "spatial disinfection card" that would provide portable virus and germ protection. None of these products are registered with the EPA. Therefore, their safety and efficacy against viruses and germs have not been evaluated. In addition, the product labeling - including directions for use - is not provided in English as required by law.

14:00 EDT EU regulators adopt new rules to monitor 'Tech Giants' - The European Union on Tuesday, adopted the Digital Services Act and Digital Markets Act, regulations proposed by the Commission in December 2020. Executive Vice-President for a Europe Fit for the Digital Age, Margrethe Vestager, said: "The European Parliament has adopted a global first: Strong, ambitious regulation of online platforms. The Digital Services Act enables the protection of users' rights online. The Digital Markets Act creates fair, open online markets. As an example, illegal hate speech can also be dealt with online. And products bought online must be safe. Big platforms will have to refrain from promoting their own interests, share their data with other businesses, enable more app stores. Because with size comes responsibility - as a big platform, there are things you must do and things you cannot do." Companies that may be impacted by this include Meta Platforms (META), Alphabet (GOOG, GOOGL), Apple (AAPL), Amazon (AMZN) and Microsoft (MSFT). Reference Link

13:14 EDT 1Life Healthcare up 14% to $9.46 after Bloomberg report of takeover interest

13:09 EDT 1Life Healthcare trading halted, volatility trading pause

12:37 EDT Infinite Reality, ReKTGlobal announce close of $470M acquisition deal - Infinite Realty announced the close of their previously reported $470M acquisition of esports and entertainment conglomerate ReKTGlobal, Inc., based on an equity valuation for iR of $2B, for a combined post-close valuation of $2.47B. As part of the deal, Infinite Reality will consolidate ReKT's entertainment and esports business into their creative tools covering social, gaming, virtual and remote production, NFT minting, UGLC, and Metaverse creation. Earlier this year, Infinite Reality announced it entered into a definitive merger agreement with NYSE-listed Universal Security Instruments, and secured a Standby Equity Purchase Agreement with Yorkville Advisors Global, LP for up to $200M upon completion of the merger with Universal Security Instruments. Completion of the announced merger with Universal Security Instruments remains subject to approval by shareholders of both Infinite Reality and Universal Security Instruments, as well as clearance by the Securities and Exchange Commission and stock exchange listing.

12:03 EDT Merit Medical announces first patient enrollend in WRAP Registry Study - Merit Medical Systems announced the successful enrollment of the first patient in its WRAP Registry Study. This study will evaluate the clinical benefits associated with the use of the WRAPSODY Cell-Impermeable Endoprosthesis in patients receiving hemodialysis that experience a narrowing or blockage of blood vessels required for dialysis. The WRAP Registry Study will enroll up to 500 patients with outflow circuit stenosis or occlusion who are receiving hemodialysis at medical facilities throughout Europe, South America, Australia, and New Zealand. Clinical outcomes of patients after the initial placement of the WRAPSODY Cell-Impermeable Endoprosthesis will be evaluated over a two-year period in accordance with the instructions for use associated with its CE Mark. "Enrollment of the first patient in the WRAP Registry Study will expand our clinical portfolio of evidence establishing the therapeutic benefits of the WRAPSODY Cell-Impermeable Endoprosthesis and provide real-world insight that can help improve the care for patients receiving hemodialysis worldwide," said Fred P. Lampropoulos, Merit Medical's Chairman and CEO.

12:00 EDT Resolute Forest falls -13.9% - Resolute Forest is down -13.9%, or -$2.02 to $12.54.

12:00 EDT Asana rises 10.7% - Asana is up 10.7%, or $1.91 to $19.79.

12:00 EDT Scor ADR rises 16.4% - Scor ADR is up 16.4%, or $3.67 to $26.00.

11:27 EDT User reports indicate problems at Instagram, says Downdetector - Reference Link

11:19 EDT Rio2's Fenix Gold project EIA not approved - Rio2 and its Chilean subsidiary, Fenix Gold Limitada announce that the Regional Evaluation Commission which includes 12 governmental institutions has voted for not approving the Environmental Impact Assessment for its Fenix Gold project in Chile. Following this decision, the Company will work on evaluating its options and decide on an action plan. Once the action plan is completed, the Company will announce how it intends to execute it and provide the revised timeline. The company said, "It is important to highlight that Fenix Gold remains with the conviction that it has provided enough technical information and studies to obtain a favorable EIA decision. This is well supported by the position from the Environmental Assessment Service with the following favorable key considerations: The Project fulfills all the applicable regulations and meets the environmental requirements for the granting of applicable sectorial permits. Fenix Gold has satisfactorily completed the Participacion Ciudadana and Consulta Indigena processes. The Fenix Gold Project is an example of modern gold mining where a full complement of technical, environmental, and social considerations have been consulted on and designed in from the outset. The Project represents a significant investment in the gold mining business in Chile by a junior mining company and will generate employment for approximately 1,200 people during the construction phase and 550 people during the 17 years' operations phase. The mine being contemplated at the Project will be a run-of-mine heap leach operation, no crushing or tailings storage facilities are required thereby minimizing the overall impact and footprint of the project."

10:03 EDT Tractor Supply appoints Andre Hawaux to board of directors - Tractor Supply Company (TSCO) announced that Andre Hawaux has been appointed as an independent member of its Board of Directors and its Audit Committee, effective July 1, 2022. Mr. Hawaux joins the Board following a 37-year career across both the consumer packaged goods and retail industries, serving most recently as COO of Dick's Sporting Goods (DKS).

10:00 EDT WPP falls -10.3% - WPP is down -10.3%, or -$5.16 to $45.18.

10:00 EDT Sylvamo falls -12.0% - Sylvamo is down -12.0%, or -$3.91 to $28.68.

10:00 EDT SIGNA Sports United rises 8.7% - SIGNA Sports United is up 8.7%, or 55c to $6.90.

09:59 EDT Anebulo Pharmaceuticals Inc trading resumes

09:54 EDT Anebulo Pharmaceuticals Inc trading halted, volatility trading pause

09:48 EDT Healthcare Capital Corp trading resumes

09:47 EDT Aegon falls -9.6% - Aegon is down -9.6%, or -43c to $4.06.

09:47 EDT SIGNA Sports United rises 8.7% - SIGNA Sports United is up 8.7%, or 55c to $6.90.

09:47 EDT Direxion Daily Semiconductor Bear 3X Shares rises 8.9% - Direxion Daily Semiconductor Bear 3X Shares is up 8.9%, or $6.55 to $79.99.

09:40 EDT Northrop Grumman selects Airbus US as provider of LEO satellite platforms - Northrop Grumman (NOC) announced the selection of Airbus U.S. Space & Defense (EADSY) as the commercial provider of satellite platforms for its proliferated-LEO constellation. Under the terms of the contract, Airbus U.S. will supply 42 satellite "bus" platforms, as well as support vehicle assembly, integration and testing. The Space Development Agency (SDA) selected Northrop Grumman in February to develop and field a portion of its Tranche 1 Transport Layer constellation. The T1TL network will deliver persistent, secure connectivity for the U.S. military and serve as a critical element for Joint All-Domain Command and Control. "The addition of Airbus U.S. as one of our key commercial suppliers complements our end-to-end satellite system integration and heritage communication mission expertise," said Blake Bullock, vice president, communication systems, strategic space systems, Northrop Grumman.

09:31 EDT Diana Shipping announces time charter contracts for M/V Electra, M/V New York - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Refined Success Limited, for one of its Post-Panamax dry bulk vessels, the m/v Electra. The gross charter rate is $17,500 per day, minus a 5% commission paid to third parties, for a period until minimum April 1, 2023 up to maximum May 30, 2023. The charter commenced on July 2, 2022. The m/v Electra was chartered to Raffles Shipping International Pte. Ltd., at a gross charter rate of $16,500 per day, minus a 5% commission paid to third parties. The "Electra" is a 87,150 dwt Post-Panamax dry bulk vessel built in 2013. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with C Transport Maritime Ltd., Bermuda, for one of its Capesize dry bulk vessels, the m/v New York. The gross charter rate is $23,000 per day, minus a 5% commission paid to third parties, for a period until minimum June 10, 2023 up to maximum August 25, 2023. The charter commenced on July 2, 2022. The m/v New York was chartered, as previously announced, to EGPN Bulk Carrier Co., Limited, Hong Kong, at a gross charter rate of $14,000 per day, minus a 5% commission paid to third parties. The "New York" is a 177,773 dwt Capesize dry bulk vessel built in 2010. The employments of "Electra" and "New York" are anticipated to generate approximately $12.48 million of gross revenue for the minimum scheduled period of the time charters.

09:26 EDT Casa Systems appoints Michael Picariello as director of investor relations - Casa Systems announced the appointment of Michael Picariello as its Director of Investor Relations. Picariello most recently served as Managing Director at JLR Consulting, a strategic consulting firm that assists both private and publicly traded tech companies with investors and communications.

09:19 EDT Yum! Brands updates on plan to exit Russia - Yum! Brands announced an update on its ongoing process to exit the Russian market. "Last month, Yum! completed the transfer of ownership of all Pizza Hut franchise assets to a local operator who has initiated the process of re-branding locations to a non-Yum! concept. The Company is also in advanced stages of transferring ownership of its KFC restaurants, operating system and master franchise rights, including the network of franchised restaurants, to a local operator. This builds on the Company's prior actions to suspend operations of all company-owned restaurants, halt all investment and restaurant development efforts, and redirect any profits from Russia operations to humanitarian efforts. Following completion of the KFC transaction, Yum! Brands intends to fully exit from Russia," the company stated. Reference Link

09:17 EDT Terreno Realty executes lease in Washington - Terreno Realty announced that it has executed a full-building lease for approximately 117,000 square feet in Kent, Washington with a nationwide building products distributor. The lease commenced June 30 and expires December 2029.

09:16 EDT JanOne's ARCA Recycling reveals new logo, website - ARCA Recycling, ARCA, a wholly owned subsidiary of JanOne, unveiled a new logo that aligns its visual identity with the innovative and environmentally responsible services it offers. "ARCA's new logo and website are reflective of the company's commitment to building a greener tomorrow," the company said. "As we have added new services, technology and locations, we have been able to diversify our customer base while providing a higher level of service," said Rachel Holmes, Executive Vice President at ARCA. "Our new brand identity reflects our evolution and our commitment to providing modern and innovative appliance recycling and energy efficiency options." The new logo and website launched on July 1, 2022. The company name and addresses will remain unchanged.

09:14 EDT Senmiao Technology launches ride-hailing platform in Harbin - Senmiao Technology announced the launch of its proprietary online ride-hailing platform for drivers in Harbin, the capital of Heilongjiang Province. Senmiao launched its online ride-hailing platform in Harbin on June 30, 2022. With the addition of Harbin, Senmiao's platform is now available in 21 cities across China, including six cities in Sichuan Province and 15 major cities in other provinces in China. Xi Wen, Senmiao's Chairman and Chief Executive Officer, stated, "We are pleased to continue strengthening our partnership with Gaode Map with the launch of our platform in Harbin, marking the eighth provincial city that Senmiao serves in China. Following our launch in Shenyang, this presents the growing opportunities for us to expand our business in Northeast China, and we look forward to providing quality online ride-hailing services to the people in Harbin. We expect to continue to launch our platform in other major cities with growth potential, which we anticipate will help improve cash flow in the coming quarters."

09:09 EDT Aravive appoints Robert Geller as Chief Medical Officer - Aravive announced the appointment of Robert B. Geller as Chief Medical Officer. Geller is a medical oncologist with over 30 years of drug development experience leading all aspects of clinical and medical affairs, including commercialization preparedness and launch of novel therapeutics. Geller will play a critical role in progressing Aravive's portfolio of programs in ovarian, renal and pancreatic cancers. Geller started his academic career as the Director of the Stem Cell Transplant program at the University of Chicago and as the Director of the Leukemia Service and Director of the Unrelated Transplant Program, Emory University. He then transitioned to community practice where he focused on the development of clinical pathways for patients with hematologic malignancies and solid tumors, and the expansion of community-based clinical research programs. After over two decades in clinical practice, he then transitioned to the biopharmaceutical industry, where he held positions in medical affairs and clinical development at Alexion, Heron Therapeutics, and most recently as Senior Vice President at Coherus Biosciences where he was involved in the clinical development and successful commercialization of both their biosimilar franchise and their immune-oncology pipeline.

09:08 EDT Mullen Automotive eliminates $17.5M in company debt - Mullen Automotive announces that it has eliminated $17.5 million in company debt and reduced its overall indebtedness from more than $30 million last year to an estimated $11 million currently. Mullen continues to strengthen its overall financial balance sheet with this recent elimination of $17.5 million dollars in company debt, which was associated with a secured convertible promissory note executed on July 23, 2020, with DBI Lease Buyback Servicing LLC, an affiliate of Drawbridge Investments. This elimination of debt leaves Mullen in its best financial health in the Company's history, with now less than an estimated $11 million left of outstanding indebtedness. This elimination of and reduction in debt is significant, considering the overall debt balance at the end of 2021 was over $30 million.

09:06 EDT CF Bankshares board increases quarterly dividend 25% to 5c per share - CF Bankshares, the parent of CFBank, NA, announced that the Board of Directors of the Company declared a quarterly cash dividend on its common stock of 5c per share, which represents a 25% increase over its previous quarterly dividend. The dividend is payable on July 26, 2022 to shareholders of record as of the close of business on July 15, 2022. Timothy O'Dell, President and CEO, commented, "This dividend increase of 25%, coming at the nine-month mark since our previous dividend increase, reflects our continued confidence in the strength of our business, along with our Board's commitment to generating attractive total returns for our shareholders."

09:06 EDT Usio CEO provides letter to shareholders - The letter said, "Usio is a company that serves various industries with diverse payment channels so our customers can collect and issue payments. This has served us well during both good and poor economic conditions. In 2020, unlike other companies in the payment space, we grew revenue as compared to 2019 because of this diversity. As one payment channel or industry was negatively impacted by the Covid shutdown, another payment channel or industry was positively impacted. The economy continues to be volatile in many areas and as we navigate these changes, we are experiencing a positive trend with certain client segments and more uncertain trends that we are watching closely, both of which I want to comment on. First, our non-bank lending segment has increased the volume of ACH transactions due to the growth in consumers loans, which naturally leads to more ACH repayments. The growth in consumer loans is also leading to an increase in returned check transactions. Returned checks are the highest margin sub-business of our ACH offering, with gross margins exceeding 80%. In the month of June, we processed more returned check transactions than we have in any month over the last eleven years. We expect to report both sequential and year over year growth in ACH returned check processing for the second quarter of 2022. Additionally, we expect to report sequential growth in total ACH transactions processed. However, as previously communicated, in the second quarter of 2022 we expect to report a year-over-year decline in the number of ACH transactions processed because this quarter will be compared to the record volume of the year ago quarter that was caused by the explosion in crypto enthusiasm. We were pleased to report that we expect the decline to be mild and the resulting revenues for ACH similar to Q2 of 2021. Second, on July 1, 2022, we became aware that one of our partners, Voyager Digital, publicly announced their intent to, "...temporarily suspending trading, deposits, withdrawals, and loyalty rewards effective at 2:00 p.m. Eastern Daylight Time today [July 1, 2022]." Usio has provided, and continues to provide, payment processing services for Voyager, and both our ACH and prepaid services for Voyager are fully available to them. We expect to continue processing transactions as requested by Voyager. However, as a result of Voyager's announcement, we believe the ACH volume of transactions we process for Voyager, and consequently our revenues, will be adversely impacted unless Voyager resumes full operations. Voyager is independent from Usio and we can't predict when, or if, Voyager will resume operations in any capacity. Voyager represented 8% of Usio's total revenue for full year 2021 and 8% of Usio's revenues from January 1, 2022 through May 31, 2022. Of the 8% of revenue generated from Voyager in 2022, 2% represented revenue derived from blank card orders for Voyager's prepaid card program, on which Usio earned no margin because we sold those cards to Voyager at cost in anticipation of future transactional revenue from card holder usage. Usio's fiscal 2022 guidance assumed only $1 million in revenue derived from Voyager's prepaid card program services for 2022. Through May 31, 2022, revenues from the prepaid card services were approximately $670,000. Thus, we expect the impact of a slowdown or end to this prepaid card program on our bottom line to be minimal. Voyager's accounts receivable balances with Usio are minimal as of July 5, 2022. Because of the strength of our new sales pipeline, potential spoilage on cards and the trends we are seeing in our non-bank lenders, we believe we will be able to replace any potential revenue shortfall from the suspended Voyager processing anticipated in our guidance. Consequently, Usio is reiterating its fiscal 2022 revenue guidance, but widening the range to 16-20% revenue growth for 2022 over 2021. As always, the revenue guidance is conditioned on favorable economic conditions. We expect the revenue replacement to be comprised of new PayFac relationships that will carry a lower margin than the margins we expected to earn on ACH transaction processing. We also have over $15 million in potential card spoilage revenue that we expect to start to recognize in September of this year and continue to recognize for the following 12-18 months. Spoilage carries significant margins that can be up to 50-80%. We believe Voyager's announcement is a temporary distraction from our rapid growth, and we expect to manage these challenges and achieve our objectives for the year consistent with our recent track record. We have initiated our share buyback plan which was previously announced and have already purchased over $400,000 of Usio stock in the open market. Finally, Usio is well positioned to capitalize on further growth opportunities leveraging our strong balance sheet with a sufficient cash balance ($7.6 Million as of March 30, 2022) and less than $115,000 in debt. I look forward to ending the year with strong growth from our PayFac and prepaid segments, and Output Solutions outperforming our expectations."

09:04 EDT IFF appoints Gebara as SVP, Commercial, Flavors - IFF announced that Nicolas Gebara has been named senior vice president, SVP, Commercial and Flavors, Nourish, effective July 1, 2022. In his 23 years at IFF, Gebara has held various roles, most recently serving as vice president, North America for Nourish. Gebara will report to Nicolas Mirzayantz, president, Nourish, IFF. Furthermore, to enhance customer experience and optimize the business, the company has announced the following appointments in the Nourish division: Carmen Cain - currently leading Flavors - has been appointed president, North America; Brian Brix - currently leading Europe - has been named vice president, Pricing and Distribution, and will also oversee IFF's global Commercial Excellence; And Jan Bechtel - currently leading the Global Key Accounts teams has been appointed, president, Europe, and will also oversee Sustainability and Diversity, Equity & Inclusion for the division.

09:04 EDT Xerox acquires print and digital marketing firm Go Inspire, terms undisclosed - Xerox has acquired Go Inspire, a UK-based print and digital marketing and communication services provider to grow its global Digital Services presence. Go Inspire serves customers throughout Europe, the Middle East and Africa. "We're focused on widening the scope of Xerox's Digital Services and Customer Engagement Services," said Darren Cassidy, UK & Ireland Managing Director and senior vice president, EMEA Global Document Services at Xerox. "Go Inspire's capabilities will support the transformation of our transactional and direct mail services into multi-channel communications, accelerate growth in EMEA and create new avenues for us to help current and new clients." This acquisition supports Xerox's commitment to expand its Digital Services business and bring innovative solutions to the workplace. Terms of the transaction were not disclosed.

09:03 EDT Marsh McLennan acquires CS Insurance Strategies, terms undisclosed - Marsh McLennan announced the acquisition of CS Insurance Strategies, a full-service insurance agency based in Chicago. Terms of the acquisition were not disclosed. Founded in 2009 by CEO Charles Smith, CS Insurance Strategies is a minority-owned brokerage providing employee health and benefits, business insurance, and risk management consulting services to organizations of all sizes across the US. CS Insurance Strategies serves clients across all industries, with specialized expertise in municipal, non-profit, and minority-owned businesses. All ten employees will join MMA.

09:02 EDT Galaxy Gaming unveils Galaxy Gaming Digital - Galaxy Gaming has launched Galaxy Gaming Digital, a division focused on online growth and development. Galaxy Gaming Digital encompasses its proprietary portfolio of table content, the brand-new Galaxy Built games developed in-house, and future digital ventures. Galaxy Gaming Digital will continue to license their table games titles to their development partners while also taking a more active role developing their own brand-new games in-house to offer more of their extensive and expanding content portfolio. For the first time, Galaxy is launching their own ready-to-play iGaming RNG titles, Galaxy Built games, pairing their new game titles with an engaging user experience. The first collection of these games includes Split to Double Blackjack, Roulette Up, and Rising Phoenix Baccarat, which are all currently available in land-based casinos. These RNG titles will launch later this year.

08:56 EDT Sandoz Canada expands generics portfolio with three products - Sandoz Canada announced a series of product launches this spring that are expanding the company's portfolio of high-quality generic medicines. During the spring, Sandoz Canada has launched the following three products. Sandoz Teriflunomide: Launched on May 16, 2022, Sandoz Teriflunomide is the company's ninth generic launch since the start of 2022. It is a generic equivalent to Aubagio, indicated as a monotherapy for the treatment of patients with relapsing remitting multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. It is available in a wallet blister format with numerated days and weeks to track medication intake. Sandoz Teriflunomide is the third multiple sclerosis treatment in the company's portfolio, following the launch of Sandoz Fingolimod in November 2019 and Sandoz Dimethyl Fumarate in October 2021. All three are supported by the Sandoz Continum patient support program. Sandoz Lurasidone: Sandoz Lurasidone hydrochloride is a generic equivalent to Latuda, indicated for the management of the manifestations of schizophrenia and, as a monotherapy or as adjunctive therapy with lithium or valproate, for the acute management of depressive episodes associated with bipolar I disorder. It is available in 20 mg, 40 mg, 60 mg and 80 mg strengths in bottles of 30. The 20 mg and 40 mg strengths are also available in bottles of 100. 120 mg will be available at a later date, also in bottles of 30. Sandoz PipTaz 40.5 g: Sandoz PipTaz 40.5 g is an addition to the Sandoz Canada portfolio's existing line of piperacillin/tazobactam powder for injection. It is indicated for the treatment of bacterial infections, such as intra-abdominal, skin, gynaecological and other infections.

08:48 EDT Zentek appoints Ilse Treurnicht to board of directors - Zentek welcomes Ilse Treurnicht to its Board of Directors. Treurnicht is Managing Partner of TwinRiver Capital, an impact investment firm focused on advancing positive environmental and social impact while delivering strong financial returns. Treurnicht has been awarded 250,000 options at a price of $2.44. These options have a 5-year expiry and vest 1/3 now, 1/3 at the 1-year anniversary date and 1/3 at the 2-year anniversary date.

08:46 EDT Jaguar Health forms Business Development Advisory Committee - Jaguar announced that it has established a Business Development Advisory Committee to identify and assess opportunities for potential alliances, mergers, and acquisitions. Rachel Zolot Schwartz has been named Chair of Jaguar's Business Development Advisory Committee. Ms. Schwartz is Vice President of Business Development and Commercial at Volastra Therapeutics, a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability.

08:40 EDT BTCS appoints Adele Carey as VP, investor relations - BTCS announced the appointment of Adele Carey as Vice President of Investor Relations to provide strategic counsel and continue the success in leading the investor relations program. Previously, Adele worked in investor relations at CrowdStreet.

08:39 EDT Valaris announces contracts and associated contract backlog of $466M - Valaris Limited announced new contracts and contract extensions, with associated contract backlog of $466M, awarded subsequent to issuing the Company's most recent fleet status report on May 2. Contract backlog excludes lump sum payments such as mobilization fees and capital reimbursements. President and Chief Executive Officer Anton Dibowitz said, "We continue to see a constructive outlook for the offshore drilling industry as evidenced by these recent contract awards for both floaters and jackups across several geographies." Dibowitz added, "We are particularly pleased to have been awarded another contract for one of our preservation stacked drillships, VALARIS DS-17, and look forward to partnering with Equinor on their flagship Bacalhau project in Brazil. We expect Brazil to be a significant growth market for high-specification floaters over the next several years and we are well-positioned to benefit by now adding a third rig to this strategic basin." Dibowitz concluded, "We have demonstrated our ability to successfully contract and reactivate stacked rigs while continuing to deliver the strong safety and operating performance that our customers have come to expect from us. We have now won contracts for five stacked floaters since the middle of last year, with three already on rate and the fourth expected to commence work soon, and we retain additional operating leverage to the improving market with eleven high-quality stacked rigs, including three uncontracted drillships, and options on two additional newbuild drillships."

08:37 EDT Bridgeline Digital reports 23 license sales totaling $690,000 in Q3 - Bridgeline Digital provided an update after the end of its fiscal Q3, which concluded on June 30. Bridgeline reported that it closed 23 license sales totaling over $690,000 in ARR in the Q3. Bridgeline's cross-selling and upsell strategy remains strong, with 11 license sales to its existing customer base on top of 12 newly won customers.

08:36 EDT Homology Medicines announces peer-reviewed publication on AAVHSC16 - Homology Medicines announced the peer-reviewed publication of data showing that AAVHSC16, one of the capsids in its family of 15 naturally occurring AAVHSCs, demonstrated low levels of tropism to the liver while maintaining robust distribution to the central nervous system, or CNS, and peripheral organs following a single I.V. administration in preclinical models. The Company believes that its unique properties, with high levels of tropism to the brain, heart and muscle, and no elevations in liver enzymes, could make AAVHSC16 an attractive capsid for new disease indications with Homology's genetic medicines platform. Homology's AAVHSC capsids differ from each other by one to four amino acids, resulting in differences in biodistribution and transduction efficiencies.

08:34 EDT Medigus announces ParaZero signed MoU with Bon V - Medigus announced that ParaZero Technologies a leading provider of autonomous drone safety systems for commercial drones and urban air mobility, or UAM, aircraft, of which Medigus has a 40% ownership stake, has signed a non-binding memorandum of understanding, or MoU, with Bon V, a leading Indian aerospace manufacturer, to integrate ParaZero SafeAir parachute recovery systems with Bon V's products. Bon V provides AI-powered, unmanned aerial vehicles, including multi-utility, heavy lift cargo vehicles. ParaZero will supply its autonomous safety systems for Bon V's range of aerial logistics platforms, ranging from 250kg to 650kg MTOW.

08:32 EDT Durect appoints Timothy Papp as Chief Financial Officer - DURECT Corporation announced the appointment of Timothy Papp as its Chief Financial Officer, CFO. In this new role, Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. Papp joins DURECT from RBC Capital Markets, where he was a Managing Director of Healthcare Investment Banking.

08:31 EDT Pingtan Marine regains compliance with NASDAQ minimum bid price requirement - Pingtan Marine Enterprise announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market dated June 29, 2022, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing of its ordinary shares on the Nasdaq Capital Market.

08:29 EDT ONCAP makes investment in Ideal Dental - ONCAP announced it has made a significant investment in Ideal Dental Management Partners, in partnership with its affiliated doctors. The company said, "Ideal Dental is a specialty dental service organization focused on providing business and administrative services to specialty dental service providers. The Company partners with doctors who independently diagnose and treat their patients, providing orthodontic, pedodontics, oral surgery and other therapeutic services. Together, they deliver exceptional care through the latest innovation and technology and the best patient experience possible - treating every patient and their family members with empathy and respect." The investment was made by ONCAP IV, Onex Corporation's $1.1 billion private equity fund. The terms of the transaction are not being disclosed at this time.

08:26 EDT Tesla's board urgers shareholders to 'vote against' reports into harassment - Tesla's board of directors is encouraging shareholders to vote against annual reporting on discrimination and harassment, additional reporting on child labor, against collective bargaining, and against an annual report on Board diversity, according to a regulatory filing for the company's annual meeting, which will be held on August 4. Tesla is currently facing 10 lawsuits alleging racial discrimination or sexual harassment, including one from the state of California.

08:26 EDT Global Crossing Airlines reports 2,418 block hours sold in Q2 - Global Crossing Airlines Group provided an update on its operations for the second quarter of 2022 and a preview of Q3 2022. "Q2 was another excellent quarter with 2,418 block hours sold versus 1,729 block hours flown in Q1 2022 for a 40% quarter over quarter increase. We added a sixth A320 for a total fleet of seven aircraft, signed LOIs for two passenger aircraft and one freighter aircraft, and signed a firm lease agreements for three A321 freighter aircraft. We also signed a major contract with TUI fly Netherlands for up to 1,600 hours in Q3, and started flying for a major client in Dominican Republic," said Ed Wegel, Chair and CEO of GlobalX.

08:24 EDT Gritstone announces inducement grants under Nasdaq lsiting rule - Gritstone bio announced that the company's Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 67,550 shares of its common stock with an exercise price of $2.66, which is equal to the closing price of Gritstone's common stock on June 23, 2022, the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees' continued employment with Gritstone on such vesting dates. The options are subject to the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

08:23 EDT 89bio announces closing of upsized $94.5M public offering of common stock - 89bio announced the closing of its upsized underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,944,252 shares of its common stock and accompanying warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549. The pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately. The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance. The offering was anchored by leading healthcare and life sciences investors including BVF Partners L.P., Deep Track Capital, RA Capital Management, Braidwell LP, Janus Henderson Investors and other institutional investors. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 89bio, were approximately $94.5 million. All of the securities were offered by 89bio.

08:22 EDT Ondas to acquire Airobotics - Ondas announced that it has signed a term sheet to acquire through acquisition or merger Airobotics, subject to the conditions described below. The addition of Airobotics is expected to help accelerate American Robotics' technical development and regulatory roadmap and expand the breath of applications, use cases and vertical markets AR targets. Each issued and outstanding share of Airobotics is expected to be converted into, and exchanged for, 0.16806 shares of Ondas common stock. The proposed acquisition or merger is subject to the satisfaction of numerous conditions, including the preparation, negotiation and execution of a definitive agreement, the receipt of any required board and shareholder approvals in respect to the proposed acquisition or merger, the satisfactory completion by Ondas of its due diligence review, and the receipt of all material third party consents. The parties have agreed to an exclusivity period until the earlier of August 4, 2022 or the execution of a definitive agreement. The parties intend to complete the proposed acquisition or merger in the second half of 2022. We can provide no assurance that a definitive agreement will be entered into or that the proposed acquisition or merger will be completed as proposed or at all. B. Riley Securities, Inc., a leading full service investment bank and wholly-owned subsidiary of B. Riley Financial, Inc. (NASDAQ: RILY), is serving as exclusive financial advisor to Ondas in connection with the proposed acquisition or merger of Airobotics.

08:21 EDT FOREWARN partners with Lakeland REALTORS - FOREWARN announced that Lakeland REALTORS has contracted to make FOREWARN services available for the 1,300+ REALTOR members it serves throughout Lakeland and the surrounding area to promote proactive real estate agent safety.

08:19 EDT Oryzon Genomics announces new financing via convertible bond program - Oryzon Genomics announced the entry into a convertible bonds financing agreement with Nice & Green in bonds convertible into new shares for a total amount of EUR 20 Million. The financing program consists of 4 tranches, one tranche of EUR 8 Million and three future optional tranches of EUR 4 Million to be drawn at the discretion of Oryzon, subject to customary conditions. The Convertible Notes have a maturity of 24 months, zero interest rate and have no warrants associated. The conversion price at which the new shares shall be issued will be 95% of the average Closing Daily VWAP of the period between conversions, but will never exceed a 9.99% discount compared to the closing price preceding the date of Conversion of the relevant CN. Oryzon has the right to execute the redemption of any or all Notes at 3% of interest. Nice & Green will, on a best effort basis, trade its equity position in both exchanges in BME with ordinary shares and in Nasdaq with ADRs. Nice & Green will have the option to participate in a future capital increase leading to a Nasdaq linked transaction subject to customary conditions.

08:16 EDT DatChat closes acquisition of Avila Security - DatChat announced the Company has closed on the previously announced acquisition of Avila Security. Pursuant to the terms of the agreement and plan of merger, the Company issued 1,000,000 shares of restricted common stock, all of which are subject to a lock-up agreement. The transaction expands DatChat's intellectual property assets through the acquisition of four issued patents and three pending applications. These assets include blockchain based digital rights management and object sharing technology, including encrypted WebRTC real-time video and audio streaming communications.

08:14 EDT NextDecade announces 1.0 MTPA LNG sale and purchase agreement With China Gas - NextDecade announced the execution of a 20-year sale and purchase agreement with China Gas Hongda Energy Trading , a wholly-owned subsidiary of China Gas Holdings Limited for the supply of liquefied natural gas from NextDecade's Rio Grande LNG export project RGLNG in Brownsville, Texas. Under the SPA, China Gas will purchase 1M tonnes per annum MTPA of LNG indexed to Henry Hub and delivered on a free-on-board basis. The LNG will be supplied from the second train at Rio Grande LNG, which is expected to start commercial operations as early as 2027. "We are pleased to announce the signing of this long-term SPA with China Gas, one of China's largest natural gas distribution companies supplying approximately 43 million households across China," said Matt Schatzman, NextDecade's Chairman and Chief Executive Officer. "This SPA demonstrates the continued acceleration of RGLNG's commercial momentum and highlights our successful strategy of offering customers flexible, competitive and low carbon-intensive LNG." "The signing of this long-term SPA with NextDecade will further optimize China Gas's portfolio, expand resource supply channels, and ensure that we can meet our customers' growing demand for quality, reliable and low carbon content energy. This SPA demonstrates China Gas's determination to unswervingly implement China's national low-carbon energy development strategy," said Yalong Qi, General Manager of China Gas Hongda Energy Trading " Based on current expected demand for LNG and assuming the achievement of further LNG contracting and financing, NextDecade anticipates making a positive final investment decision on up to three trains of the Rio Grande LNG export project in the second half of 2022, with FIDs of its remaining trains to follow thereafter.

08:12 EDT PowerFleet selected as preferred partner by AXA Seguros - PowerFleet announced it has been selected by AXA Seguros, one of the largest insurance companies in Mexico, as a preferred partner of its fleet technology solutions. Led by PowerFleet's Mexico subsidiary, Pointer, the partnership will look to help AXA strengthen its value proposition with the commercial heavy-duty fleets segment by helping customers improve operations and risk management through advanced telematics. After a 60-day trial, AXA Seguros recognized the added value Pointer by PowerFleet MX solutions brought to help them differentiate from the competition in the commercial fleets segment. Vehicle theft is a significant issue in Mexico.

08:12 EDT Vertex Pharmaceuticals announces FDA lifts clinical hold on VX-880 trial - Vertex Pharmaceuticals announced that the FDA has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. As a result, the Phase 1/2 trial will be reopened for screening, enrollment and dosing at multiple sites in the U.S. To date, three patients have been dosed in the Phase 1/2 study with VX-880. Two patients received half the target dose of cells in Part A of the study. A third patient has received the full target dose in Part B of the study. Part B will evaluate safety and efficacy in five patients at the target dose before expanding to additional patients in Part C.

08:11 EDT Xperi acquires Vewd Software Holdings for $109M - Xperi Holding announced it has acquired Vewd Software Holdings for $109M through a mixture of cash and debt. Vewd is a global provider of over-the-top and hybrid TV solutions that ship in more than 30M connected TV devices annually. The acquisition establishes Xperi as a leading independent streaming media platform through its TiVo brand and the largest independent provider of Smart TV middleware globally. Furthermore, the transaction gives Xperi access to an installed European footprint of approximately 15 million devices that can be enabled for monetization, including activation of TiVo+, a free ad-supported TV service. Vewd Software Holdings Limited, founded in 2002 with main offices in Norway, Sweden, Taiwan and Poland, is an independent OTT software provider for Smart TV makers, connected car and video-over-broadband operators. Over 450 million connected TV devices have shipped with Vewd Smart TV Solutions from customers that include Amazon, Commscope, Hisense, Nintendo, Sagemcom, Skyworth, Sony, Swisscom, TCL, TPV Phillips and Vestel.

08:10 EDT Shell, AMG Recycling, Aramco enter agreement for supercenter complex - Shell & AMG Recycling and its partner, the United Company for Industry announced the signing of an agreement with the Saudi Arabian Oil Company under which SARBV and UCI shall construct and operate a world-class 'Metals Reclamation Complex' for the recovery and recycling of metals in Al-Jubail Industrial City, in Saudi Arabia. The Agreement is in support of the Kingdom's [Vision 2030] ambitions to accelerate energy transition, achieve sustainability aspirations and drive circular investment in the Kingdom, and in alignment with the Aramco Namaat Industrial Investments Program initiative that aims to build national champions, create a robust industrial ecosystem and introduce unique job opportunities. As the Kingdom and the GCC region are becoming globally pivotal for the supply and demand of the metal, vanadium, as well as the upgrading of the bottom-of-the-barrel, the Metals Reclamation Complex seeks to enable the development of a world-class and regional facility for processing refineries' recyclable materials into valuable products. In support of this initiative, this Agreement aims to be the initial phase of the Supercenter complex, with the processing of the metal vanadium concentrate from the Jazan Integrated Gasification Combined Cycle Plant, licensed by Shell, to produce high-purity Vanadium Pentoxide; build a regional research and development center for testing a residue-upgrading catalyst; install a Lithium Vanadium Battery; and install a vanadium electrolyte production plant, an important step in the development of a market for Vanadium Redox Flow Batteries in the Kingdom. The Agreement also addresses later phases of the visionary "In-Kingdom Supercenter" that include expanding recycling capabilities, as well as a regional hub for spent residue catalysts metals reclamation, and fresh residue-upgrading catalyst manufacturing. This unique combination of capabilities, all in one place, will provide an end-to-end solution for refiners, and aim to accelerate growing niche downstream industries in the Kingdom.

08:09 EDT Precigen enters agreement to divest non-healthcare subsidiary Trans Ova to URUS - Precigen announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics to URUS, a holding company with cooperative and private ownership, for $170M in upfront cash and up to $10M earn-out based on the performance of Trans Ova in 2022 and 2023. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. "We believe this transaction will support Precigen's mission as a premier cell and gene therapy company laser focused on the rapid development of our top clinical assets to maximize shareholder value and potentially improve the way devastating diseases like cancer are treated," said Helen Sabzevari, PhD, President and CEO of Precigen. "I am proud of Precigen management and the Trans Ova team for successfully leading the financial turnaround of Trans Ova operations to maximize the value of this asset over the last two years. We expect to have the capacity to pay the convertible notes upon maturity and to focus on fast regulatory paths for our healthcare portfolio."

08:08 EDT Applied UV says partner MedLine places 'large order' for S200 system - Applied UV, announces MedLine, its exclusive North American Scientific Air Management healthcare distribution partner, has placed a large multi-unit follow-on order for its patented S200 mobile air purification system. The follow-on order for our mobile S200 air purification is in further support of the Centers for Medicare and Medicaid Services Policy announced earlier in the year to ease visitation in Long-term Care facilities. Under the CMS policy guidance, it provides funding available for long-term care providers looking to make air quality upgrades to their facilities to reduce the spread of COVID-19.

08:07 EDT Janel to launch cash tender offer to acquire 45% interest in Rubicon - Rubicon Technology announced that it has entered into a definitive Stock Purchase and Sale Agreement with Janel Corporation, pursuant to which Janel will commence a cash tender offer to purchase up to 45% of the outstanding shares of Rubicon's common stock on a fully-diluted basis at a price of $20.00 per share. The offer price represents approximately 120% premium to the Company's closing stock price on the NASDAQ of $9.10 on July 1, 2022. The Sale Agreement and the transactions contemplated thereby have been unanimously approved by the board of directors of both companies. Janel's obligation to complete the tender offer, among other things, is subject to the receipt of at least 35% of the outstanding shares of Rubicon's common stock on a fully-diluted basis. Upon completion of the tender offer, Rubicon will distribute cash in the amount of $11.00 per share to the Company's stockholders. Upon closing of the tender offer, two of Rubicon's current directors will resign and Janel will have the right to select two individuals to fill the vacancies created by the resignations. As soon as practicable subsequent to the tender closing and the Distribution, Rubicon intends to commence the process to voluntarily delist from the Nasdaq Stock Market and deregister its securities with the Securities and Exchange Commission. Bandera Partners LLC, Sententia Capital Management LLC, Poplar Point Capital Management LLC and Aldebaran Capital, LLC, the Company's four largest stockholders, have entered into agreements with Janel respectively committing to tender all of their Rubicon common stock on the same terms as all of Rubicon's other stockholders. It is anticipated that the tender offer will commence within the next 10 business days, with the closing anticipated to be approximately 30 days thereafter. The closing of the tender offer is subject to customary conditions, as well as the 35% minimum condition. The tender offer is not subject to a financing contingency.

08:06 EDT IceCure Medical announces Glick will serve as a strategic advisor - IceCure Medical announced that Gilad Glick will serve as a strategic advisor to the Company, to guide its commercialization strategy up to execution. Glick will support the acceleration of IceCure's Go-to-Market operations for global adoption of ProSense with a special focus on the U.S. and EU markets. Glick was CEO of Itamar Medical from 2013 through 2022.

08:04 EDT Bragg Gaming announces Spin Games goes live in Connecticut - Bragg Gaming (BRAG) announced that its wholly-owned B2B gaming technology and content provider, Spin Games, is now live in Connecticut with its Remote Game Server, or RGS. The Spin Games RGS and an initial library of 11 titles are available to players in the state via the DraftKings (DKNG) and Mashantucket-Pequot Tribe iGaming sites.

08:02 EDT Chinook Therapeutics' BION-1301 receives orphan drug designation in Europe - Chinook Therapeutics announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy, or IgAN. The decision follows a positive opinion from the Committee for Orphan Medicinal Products, or COMP, of the European Medicines Agency, or EMA.

07:56 EDT Lexagene Holdings announces webinar on use of MiQLab System - LexaGene Holdings announced that University of California-Davis Professor Dr. Jane Sykes BVSc, PhD, MBA, DACVIM will present a webinar entitled, "The Wave of the Future: In-Clinic PCR Diagnosis." This will be a live event hosted by DVM360 and moderated by Adam Christman, DVM, MBA. It is scheduled for Tuesday July 26th at 7 PM EST. This webinar will provide background information on the difficulties of accurately diagnosing urinary tract infections with conventional technologies. Also, the course will provide background information on the rising threat of antimicrobial resistance. This will be followed by an overview of PCR and how genomic testing can be used by veterinarians to make rapid evidence-based decisions in the clinic by utilizing the MiQLab System to rapidly screen samples for 10 common pathogens and 33 markers for antimicrobial resistance factors.

07:43 EDT AUDACIOUS appoints Jill Swainson to board of directors - Australis Capital announced that Jill Swainson has been appointed as member of the Board of Directors. Swainson will replace Avi Gellar who served as board member since November 2020, and who has resigned for personal reasons. Swainson formerly served as chief legal counsel at Aurora.

07:41 EDT Proxy advisors recommend Mason Graphite shareholders vote for NMG agreement - Mason Graphite is pleased to announce that Institutional Shareholder Services and Glass Lewis have recommended that Mason Graphite shareholders vote "FOR" the option and joint venture agreement ) with Nouveau Monde Graphite and the change of business/ Shareholders will benefit from the proposed joint venture to be formed with NMG under the OJV Agreement by: Leveraging NMG's expertise and commercialization capabilities, which will also allow to realize the full potential of the Lac Gueret property by increasing its scope of production to a minimum of 250,000 tonnes per annum of graphite concentrate; Accessing NMG's Demonstration Plant necessary to advance the project; an estimated value of C$30 million; Investments by NMG for a total of C$15M: C$10 million in the Lac Gueret project prior to the formation of the Joint Venture; C$2.5 million in equity of Mason Graphite at C$0.50 per share promptly after shareholders' approval; and C$2.5M in equity of Mason Graphite at the formation of the Joint Venture at a price per share established on a 20-day volume weighted average price at the time of investment, with a floor price of C$0.50. In reaching its recommendation that Mason Graphite shareholders vote "FOR" the OJV Agreement, ISS stated: "The joint venture arrangement makes strategic sense as it enables the company to act on the new company business model, while minimizing the costs associated with exploration and further development. The company appears to have conducted a lengthy strategic alternative review and in light of there being no significant governance concerns, shareholder approval of this resolution is warranted." In reaching its recommendation that Mason Graphite shareholders vote "FOR" the Change of Business, ISS stated: "Given that the change of business will formally align the company with its already current business activities and is being done to comply with TSXV policies, and in the absence of other significant corporate governance concerns, shareholder approval of this resolution is warranted." As of July 4, 2022, the total votes cast represent 12.98% of the total shares issued and outstanding and both resolutions are being supported by 99.7% of the vote cast.

07:38 EDT Digihost reports Q2 BTC production up 128.9% from last year - Digihost Technology provided unaudited comparative BTC production results for the month and quarter ended June 30 combined with an operations update. The Company mined approximately 141.71 more BTC in Q2, compared to Q2 2021, representing an increase of approximately 128.9%..All monetary references are expressed in USD unless otherwise indicated. Production highlights for June include: Mined 72.18 BTC, resulting in total holdings of 293.30 BTC at the end of June valued at approximately $5.8M based on a BTC price of $19,785 as of June 30; Ethereum holdings of 1,000.89 ETH at the end of June valued at approximately $1.07M based on an ETH price of $1,067.29 as of June 30; Total digital asset inventory value, consisting of BTC and ETH, of approximately $6.87M as of June 30. In addition, the Company held cash of approximately $5M and derivative instruments of approximately $500,000 as of June 30, 2022. Cash and liquid assets as of June 30 totalled approximately $12.4M. On June 14 the Company repaid its $10M collateralized loan facility by monetizing a portion of its BTC holdings. The Company currently has no debt. To avoid equity dilution for its shareholders, management sold a portion of its BTC production during the month to fund its energy costs.

07:37 EDT Tornado Global Hydrovacs signs strategic supply agreement with Ditch Witch - Tornado Global Hydrovacs announced that it has entered into a Product Supply and Development Agreement for the co-development and supply of customized hydrovac trucks with Ditch Witch, a division of The Toro Company. The Supply Contract contains a commitment for the delivery of a number of innovative, proprietary hydrovac trucks to the Purchaser that are estimated to generate minimum gross revenue for Tornado in the amount of $43,850,000 during the four year term. The Supply Contract requires Tornado to co-develop a customized exclusively Ditch Witch branded hydrovac truck, and then supply the customized hydrovac trucks to the Purchaser commencing in fiscal year 2022 and ending in fiscal year 2025, subject to certain customary commercial terms and conditions. The sale and delivery of the first customized hydrovac truck to the Purchaser is expected to be completed in Q3 2022.

07:35 EDT Chalice Brands enters amended agreement to acquire Cannabliss locations - Chalice Brands announces that the Company signed an amending agreement July 1, 2022 to improve the terms of its previously disclosed Asset Purchase Agreement, which was originally executed on September 16, 2021, to acquire four retail stores branded Cannabliss & Co. from Acreage Holdings, for total consideration of $6,500,000. The closing of the transaction as amended by the Amending Agreement is subject to approval by the Oregon Liquor and Cannabis Commission and the satisfaction of other closing conditions. The OLCC approval is expected to occur within the next 30 days. Upon execution of the Amending Agreement, Chalice Brands will acquire the assets of the four Cannabliss branded retail locations for total consideration of $6,500,000, consisting of a $250,000 payment already made at the time the original agreement was signed, plus an additional $100,000 in cash at closing, offset by a deduction of $300,000 from the Purchase Price to settle the accounts payable to Chalice Brands. Chalice Brands will pay the balance owed of $5,850,000, by way of a 36-month secured promissory note carrying accrued interest at a rate per annum equal to 12%. Chalice Brands shall make the following balloon payments to Acreage: $1,000,000 on January 1, 2024 and $1,000,000 on January 1, 2025, and on January 1, 2026, Chalice Brands shall pay all amounts owed to Acreage under this Note, if any. Chalice Brands acquires four Cannabliss & Co. retail locations further expanding our statewide retail footprint in Oregon to a total of 18 locations with iconic dispensary locations added such as the Fire Station store in Southeast Portland.

07:33 EDT Dyne Therapeutics announces FDA clearing of clinical trial of DYNe-25 - Dyne Therapeutics announced that the FDA has lifted the clinical hold and cleared its Investigational New Drug, or IND, application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy, or DMD, amenable to skipping exon 51. The Company expects to begin dosing patients in a Phase 1/2 clinical trial evaluating DYNE-251 in mid-2022. Dyne plans to evaluate DYNE-251 in a global, randomized, placebo controlled, multiple ascending dose (MAD) clinical trial with a long-term extension study. The trial aims to enroll 30 to 50 ambulant and non-ambulant males with Duchenne, who are age 4 to 16 and have mutations amenable to exon 51 skipping therapy. The study will evaluate safety, tolerability, dystrophin expression as measured by Western Blot, pharmacokinetics and pharmacodynamics, and measures of muscle function. Dyne plans to outline additional details regarding the trial design and timing of data upon initiation of dosing.

07:33 EDT Trane CEO issues statement on West Virginia v. EPA ruling - Dave Regnery, chair and CEO of Trane Technologies, issued the following statement regarding the 6-3 ruling from the Supreme Court of the United States in the environmental enforcement case West Virginia v. EPA. "The urgency to solve for climate change grows greater every day, and Trane Technologies has made it our purpose to boldly challenge what's possible for a sustainable world. With the recent Supreme Court ruling on climate, there is an even greater imperative for Congress to work in a bipartisan way to bring effective climate legislation forward. The technology to solve climate change already exists today - we now need to scale it up and accelerate adoption. It will take industry, government, NGOs and citizens working together to protect our planet. We will continue to work closely with the White House and with lawmakers to help shape sound climate policy and legislation to build a sustainable future for generations to come."

07:31 EDT Auxly Cannabis receives $6M on sale of Auxly Annapolis Facility - Auxly Cannabis Group announced that the Company has closed the sale of its Auxly Annapolis indoor cultivation facility located in Kentville, Nova Scotia to a private purchaser for total proceeds to the Company of $6M. As previously announced by the Company, Auxly ceased operations at the cultivation facility in February 2022. The Company intends to apply the proceeds from the sale to support Auxly's ongoing operations. "We are pleased with the sale of our Annapolis indoor facility," said Hugo Alves, CEO. "Being able to monetize this non-core asset to strengthen our cash position in a non-dilutive way is fantastic for the company and provides us with additional capital to support Auxly's strategic objectives."

07:20 EDT CureVac files patent infringement suit in Germany against BioNTech - CureVac N.V. (CVAC) announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Dusseldorf against BioNTech (BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights, EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1 and DE 20 2015 009 974 U1, utilized in the manufacture and sale of Comirnaty, BioNTech and Pfizer's (PFE) mRNA COVID-19 vaccine. CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer. The company said, "The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others. These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression, as well as mRNA vaccine formulations specific to SARS CoV-2 vaccines. Over the last 22 years, CureVac developed proprietary foundational technology related to mRNA design, delivery and manufacturing that materially contributed to the development of safe and efficacious COVID-19 vaccines. CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health. This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology. Accordingly, CureVac's intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life saving medicines."

07:18 EDT Miromatrix applauds FDA for hosting an organ transplant discussion - Miromatrix Medical applauds the FDA for hosting a two-day public advisory committee meeting to discuss scientific and regulatory topics relating to the field of organ transplant, specifically xenotransplantation. Opening remarks from the FDA highlighted the limited availability of human organs for transplant and recognized the tremendous unmet need for new treatments for patients with end-stage organ failure. The FDA published its original guidance for the xenotransplantation industry in 2003 and updated that guidance in 2016. The FDA noted that the updated guidance addresses many of the topics discussed during the two-day meeting and that the science is changing rapidly.

07:17 EDT LiveOne, ZYNC announce multi-year partnership - LiveOne announced it partnered with the ZYNC to exclusively deliver personalized in-car audio and video music entertainment. The deal will see LiveOne's streaming content roll out on ZYNC-enabled Mercedes-Benz vehicles in late 2022 - with additional electric and autonomous driving vehicles to be announced later this year. "We are excited to partner with ZYNC to deliver our streaming video and audio music content through their cutting-edge in-car digital entertainment platform," said Dermot McCormack, President, LiveOne. "ZYNC customers will have the opportunity to unlock a universe of digital experiences from LiveOne including live concerts, vodcasts, pay-per-view events, festivals and virtual meet and greets. This partnership truly elevates the time spent in our cars and gives consumers the ultimate personalized immersive in-car experience."

07:15 EDT American Lithium appoints Ted O'Conner as EVP, exploration and development - American Lithium announced the appointment of Claudia Tornquist to the Board of Directors and Ted O'Connor as Executive Vice President of the Company. Tornquist, benefiting from many years of experience in the mining industry, serves currently as President, CEO, and director of Kodiak Copper Corp. Mr. O'Connor will be transitioning from his current role as a Company director and chair of the audit committee to a more hands-on role as Executive Vice President of Exploration and Development. Mr. O'Connor is a professional geoscientist with over 30 years of experience in the exploration industry. Previously, he served as CEO and a director of Plateau Energy Metals, which was acquired by American Lithium last year. In connection with the above appointment of Claudia Tornquist and the appointment of two key consultants, the Company also announces that it has granted an aggregate of 250,000 incentive stock options and 225,000 restricted share units in accordance with the Company's incentive plan, and as compensation for ongoing services rendered to the Company. The Options vest over a period of 12 months and are exercisable at a price of $1.91 until July 4, 2027. Each RSU represents the right to receive, once vested, one common share in the capital of the Company. The RSUs vest on July 4, 2024, subject to earlier vesting in the event of a change of control and subject to the polices of the TSX Venture Exchange.

07:14 EDT Xos delivers four 100% battery-electric vehicles to return customer Loomis - Xos announced the delivery of four of its 100% battery-electric vehicles to return customer Loomis, a cash-handling company across North America. The four locations include Montebello, Calif., Hayward, Calif., Moonachie, N.J., and Charlotte, N.C.

07:12 EDT MeaTech 3D's subsidiary establishes avian cell line with upscaling path - MeaTech 3D announces that Peace of Meat, the company's Belgian wholly-owned subsidiary, has established a stable and unique avian cell line with a clear upscaling path. In May 2022, Peace of Meat signed a joint development agreement with ENOUGH, a leader in the field of mycoprotein. The initiative will combine Peace of Meat's unique expertise in cultured avian development with ENOUGH's cutting-edge mycoprotein ingredient to create game-changing hybrid alternative meat products. Dirk Standaert, Peace of Meat's Chief Executive Officer: "We are moving forward with a clear R&D and go-to-market strategy. We have established a superior cell platform for the industrialization of cultured meat products that allows us to develop tasty, nutritious cultured avian products made sustainably."

07:12 EDT Meta Materials and Coulometrics team to develop next generation batteries - Meta Materials announced it has signed a Master Service Agreement with Coulometrics a provider of battery material development services, state-of-the-art battery assembly and testing services, and toll coating and battery contract manufacturing, to independently validate META's platform technologies related to battery applications "With the recent strategic acquisitions of Plasma App and Optodot, combined with our roll-to-roll high volume thin-film coating production facility in Quebec, we now have capabilities to make Li-ion batteries safer and more efficient." said George Palikaras, President & CEO of META. "We are excited about our collaboration with Coulometrics, a world class battery developer. Leveraging Dr. Buiel's 28-year expertise and state-of-the-art materials synthesis and battery assembly facility, META and Coulometrics will collaborate to develop and test the safety and performance of our new battery technologies, which we believe will enable a new generation of safer lithium-ion batteries.

07:10 EDT CollPlant to present, exhibit at TERMIS annual conference - CollPlant announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society, TERMIS, in Toronto, Canada, on July 10-13, 2022. "We look forward to participating at the TERMIS conference, a leading organization in the field of tissue engineering and regenerative medicine," said Yehiel Tal, CollPlant's Chief Executive Officer. "We will deliver two presentations demonstrating the unique biological and physical properties of rhCollagen-based compositions, which provide the flexibility to formulate a wide variety of biomaterials that are designed for different regenerative medicine applications including bioprinting of organs and tissues, soft and hard tissue reconstruction, and skin rejuvenation. We will also have an exhibition booth where our marketing and R&D team will interact with researchers, scientists, and clinicians from both academia and industry to showcase our products."

07:09 EDT Allena reschedules special meeting to approve reverse stock split - Allena Pharmaceuticals announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the Allena stockholders entitled to vote thereat, will be determined in the near future, and will be will be included in supplemental proxy materials to be filed with the SEC and distributed to stockholders promptly after the new record date.

07:08 EDT BioXcel Therapeutics appoints Michael Miller to board of directors - BioXcel Therapeutics (BTAI) announced the appointment of Michael Miller to its Board of Directors, effective July 1, 2022. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals (JAZZ).

07:07 EDT Nevro announces 12-month results from SENZA-PDN randomized controlled trial - Nevro announced that the complete 12-month results from the SENZA-PDN Randomized Controlled Trial, RCT, including health-related quality of life, HRQoL, outcomes in patients with Painful Diabetic Neuropathy, PDN, treated with high-frequency 10 kHz spinal cord stimulation, SCS, were published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes. High-Frequency 10 kHz Spinal Cord Stimulation Improves Health-Related Quality of Life in Patients with Refractory Painful Diabetic Neuropathy: 12-Month Results From a Randomized Controlled Trial: The published data in the Mayo Clinic Proceedings showed treatment with 10 kHz Therapy resulted in significant pain relief and multiple significantly improved metrics of HRQoL. Results included significantly less pain interference with sleep, mood, and daily activities. Importantly, at 12 months, 10 kHz SCS treatment resulted in improvement in overall HRQoL that was 2.5- to 4.5-fold higher than the minimally clinically important difference. Furthermore, over 70% of clinicians and patients reported overall improvement as better or a great deal better than the pre-SCS baseline. These outcomes were durable over 12 months and support 10 kHz SCS treatment in patients with refractory painful diabetic neuropathy. In addition, approximately 92% of participants were satisfied or very satisfied with 10 kHz Therapy. The SENZA-PDN study is the largest RCT conducted to date for SCS treatment of PDN. Compared with pharmacotherapy, high-frequency 10 kHz SCS resulted in more profound pain relief and pronounced HRQoL improvements, including well-being, sleep quality and function. The company expects the complete 24-month data from the SENZA-PDN RCT to be available in the fourth quarter of 2022 and plans to submit this data set for presentation at NANS in January 2023 and publish as soon possible thereafter.

07:06 EDT Hecla Mining to acquire Alexco Resource for 47c per share - Hecla Mining (HL) and Alexco Resource (AXU) announced a definitive agreement for Hecla to acquire all of the outstanding common shares of Alexco that Hecla does not already own. Each outstanding common share of Alexco will be exchanged for 0.116 of a share of Hecla common stock implying consideration of 47c per Alexco common share and a premium of 23% based on the companies' five-day volume weighted average price on the NYSE and NYSE American on July 1. In addition, Hecla will provide interim financing to provide working capital and ensure the development and exploration at Keno Hill continues to be advanced and subscribe for additional common shares bringing its ownership stake to 9.9%. Hecla has also entered into an agreement with Wheaton Precious Metals Corporation (WPM) to terminate its silver streaming interest at Alexco's Keno Hill property in exchange for $135M of Hecla common stock conditional upon the completion of Hecla's acquisition of Alexco. The agreement provides Alexco shareholders with 0.116 of a Hecla share for each Alexco common share they hold as of the effective date of the agreement. Hecla will issue approximately 18M common shares to Alexco shareholders. Upon completion of the transactions with both WPM and Alexco, and assuming the July 1 five-day volume weighted average price of Hecla's shares of $4.13, WPM and Alexco shareholders will own approximately 5.6% and 3%, respectively, of the outstanding common shares of Hecla. The exact number of Hecla common shares to be issued to WPM will be calculated immediately before the closing date. Hecla is providing Alexco with a $30M secured loan facility and is purchasing 8,984,100 Alexco Shares at C$0.50 per share, having an aggregate value of C$4,492,050, which will result in 9.9% of Alexco Shares being held by Hecla or its affiliates. A portion of the loan will be immediately drawn and the remainder available on a revolving basis, and the use of proceeds will be for agreed upon working capital and capital expenditures purposes according to a plan jointly approved by Alexco and Hecla. The loan and share purchase are intended to provide Alexco with immediate working capital to continue development work at Keno Hill and are not conditional upon the completion of the transaction. The board of directors of Alexco and Hecla have both unanimously approved the transaction. The board of Alexco unanimously recommends that Alexco shareholders vote in favor of the transaction. Alexco's directors and officers support the transaction and have entered into customary voting support agreements with Hecla agreeing to vote their Alexco shares in favor of the transaction. WPM has also entered into a voting support agreement with Hecla to vote its Alexco shares in favor of the transaction, resulting in approximately 4.9% of Alexco's outstanding common shares being subject to voting support agreements to support the transaction. Cormark Securities provided an opinion to the Alexco board of directors that the transaction is fair from a financial point of view to Alexco shareholders as of the date of the arrangement agreement, and subject to the assumptions, limitations and qualifications in the opinion. The transaction will be implemented by a court-approved plan of arrangement under the Business Corporations Act and requires the approval of: 66 2/3% of the votes cast by the holders of Alexco's common shares, 66 2/3% of the votes cast by the affected securityholders of Alexco voting as a single class, and if applicable, a majority of the votes cast by the holders of Alexco's common shares after excluding any votes of Hecla and other persons required to be excluded under Canadian Multilateral Instrument 61-101 Protection of Minority Security Holders in special transactions, all at a special meeting. The Alexco-Hecla and WPM-Hecla transactions are each subject to applicable regulatory approvals and customary closing conditions. The agreement provides for customary deal-protection provisions, including a non-solicitation covenant on the part of Alexco, a right for Hecla to match any superior proposal and a termination fee of $10M, payable by Alexco to Hecla, under certain circumstances. It is anticipated that the special meeting will be held in September 2022 with the acquisition expected to close later that month.

07:05 EDT Bio-Techne completes acquisition of Namocell - Bio-Techne Corporation announced it has completed the acquisition of Namocell. "The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. Namocell's instruments and consumables are critical technologies in various workflows in both biotherapeutics and diagnostics, including cell and gene therapy development and commercialization, cell engineering, cell line development, single cell genomics, antibody discovery, synthetic biology, and rare cell isolation," the company said.

07:04 EDT Lyra Therapeutics appoints Nieman as Chief Medical Officer - Lyra Therapeutics (LYRA) announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022. Dr. Nieman brings more than 25 years of experience in drug development and medical affairs. Dr. Nieman has had prior leadership roles as SVP & Worldwide Medical Head of Immunology at Bristol Myers Squibb (BMY), Head of R&D China at BMS, Global Medical Officer & Head of Medical at Teva (TEVA), and Head of Asia Pacific Medical at Bayer (BAYRY).

07:01 EDT Wheaton enters pact with Hecla Mining to terminate Keno Hill silver stream - Wheaton Precious Metals (WPM) announced that it has entered into a definitive agreement with Hecla Mining (HL) to terminate its silver stream on Alexco Resource's (AXU) Keno Hill Silver District in the Yukon, Canada for $135M. On July 5, Hecla announced its intention to acquire Alexco through a definitive arrangement agreement, which remains subject to shareholder and regulatory approvals. The termination of the Keno Hill silver stream is conditional upon Hecla completing its announced proposed acquisition of Alexco together with other customary approvals. As consideration for the termination of the Keno Hill silver stream, Hecla will issue to Wheaton $135M of Hecla common shares. Subsequent to the closing of the termination of the Keno Hill silver stream, Wheaton will own approximately 5.6% of Hecla's issued and outstanding common shares. The exact number of Hecla common shares to be issued will be calculated immediately before the closing date. The closing of the transaction with Hecla, including the termination of the Keno hill stream, is subject to Hecla closing its acquisition of Alexco and other customary conditions.

06:57 EDT KalVista presents data for sebetralstat, Factor XIIa inhibitor program - KalVista Pharmaceuticals has presented data for its oral on demand plasma kallikrein inhibitor and Factor XIIa programs at the EAACI2022 conference in Prague, Czech Republic. KalVista presented data showing sebetralstat was an effective treatment for both peripheral and abdominal attacks with 80% of attacks achieving symptom relief within 12 hours, regardless of attack location. Population pharmacokinetic data showed that the PK of sebetralstat did not appear to be affected by consumption of a normal meal prior to dosing compared with taking the dose after fasting. Furthermore, PK modeling supports the use of sebetralstat in adolescents 12 years and older without dose adjustment. Animal model data with oral FXIIa inhibitor KV998086 showed the compound protected mice from kallikrein-kinin system mediated edema. KV998086 blocked the generation of FXIIa & PKa and prevented HK cleavage in a dose-responsive manner. Pharmacokinetic studies showed that oral KV998086 displayed high bioavailability. Inhibition of the KKS with KV998086 may provide an opportunity for once-daily HAE prophylaxis as well as having potential to treat other KKS-mediated diseases.

06:55 EDT Ra Medical Systems receives FDA 510(k) clearance for DABRA 2.0 catheter - Ra Medical Systems announces receipt of U.S. Food and Drug Administration 510(k) clearance for the Company's DABRA 2.0 catheter as part of the DABRA Excimer Laser System. This next-generation DABRA catheter features enhancements including a braided overjacket design that's intended to improve deliverability and kink resistance when navigating tortuous anatomy, as well as a six-month shelf life. On May 16, 2022 Ra Medical Systems disclosed that its Board of Directors is reviewing strategic alternatives with the goal of maximizing shareholder value. In conjunction with this review, on June 6, 2022 the Company filed a report on Form 8-K with the Securities and Exchange Commission announcing initiation of a reduction in force under which approximately 65% of the Company's full-time employees were terminated. Non-terminated employees were offered conditional retention arrangements for a period of approximately 60 days from the date of the filing to allow for evaluation and monitoring of the Company's near-term personnel needs based in part on the Company's financial status and the Board's review of strategic alternatives. The purpose of the reduction in force is to preserve capital with the goal of maximizing the opportunities available to the Company during the Board's review of strategic alternatives.

06:52 EDT Ring Energy to acquire Stronghold's Permian Basin assets for $465M - Ring Energ, announced it has entered into an agreement to acquire the assets of privately-held Stronghold Energy II Operating, LLC and Stronghold Energy II Royalties. Stronghold's operations are located primarily in Crane County, Texas and focused on the development of approximately 37,000 net acres in the Permian Basin's Central Basin Platform. Stronghold is majority owned by Warburg Pincus. Consideration for the Transaction, subject to customary closing adjustments, consists of: $200.0 million in cash at closing; $15.0 million deferred cash payment due six months after closing; $20.0 million of existing Stronghold hedge liability; and $230.0 million in Ring equity based on a 20-day volume weighted average price of $3.60 per common share as of June 30, 2022, all of which will be issued to the owners of Stronghold. The cash portion of the consideration will be funded primarily from borrowings under a fully committed revolving credit facility to be underwritten by Truist Securities, Citizens Bank, N.A., KeyBanc Capital Markets and Mizuho Securities. The borrowing base of the Company's $1.0 billion Credit Facility will be increased from $350.0 million to $600.0 million upon closing of the Transaction. The equity component of the consideration will be approximately 21.3 million shares of Ring's common stock based on a 20-day VWAP of $3.60 per share as of June 30, 2022, and 153,176 shares of new Series A convertible preferred stock that will be automatically converted to common stock upon stockholder approval of the conversion into approximately 42.5 million shares of common stock at the equivalent price of $3.60 per common share. The effective date of the Transaction is June 1, 2022 and closing is anticipated in the third quarter of 2022. Expected to substantially enhance financial position by increasing free cash flow generation and lowering operating costs Proven, high-quality asset base with substantial, capital efficient and low break-even-cost inventory is expected to be immediately accretive to the following metrics: Cash flow per share; FCF per share; FCF yield; Net production per share; Net proved reserves per share; Return on capital employed. High quality, high margin CBP assets are expected to immediately lower the following metrics; Lease operating costs per barrel of oil equivalent; Gathering, processing and transportation per Boe; and General and administrative expense per Boe. Expected to strengthen balance sheet and accelerate ability to pay down debt; Expected to lower 2022 year-end leverage ratio on a combined basis of below 1.5 times versus previous target of below 2.0 times for Ring on a standalone basis; Accretive FCF generation expected to accelerate debt repayment. Q4 2022 estimated pro forma Company metrics: 18,000 - 19,000 barrels of oil equivalent per day; $82 - $86 million Adjusted EBITDA; and $50 - $54 million capital expenditures. Following the closing of the Transaction, Stronghold's owners will own approximately 34% of Ring and become its largest stockholder. The closing of the Transaction is subject to customary closing requirements, including satisfactory review of title and environmental conditions. The Transaction was approved by a unanimous vote of Ring's Board of Directors. Following the closing of the Transaction, the Board will be expanded from seven to nine directors to include two members proposed by Warburg Pincus. Ring's current senior management team will continue to lead the pro forma Company.

06:40 EDT Planet 13 Holdings closes on Florida property acquisition for $3.3M - Planet 13 Holdings announced it has finalized the purchase of a 23-acre parcel, with a 10,500 square foot building currently located thereon, for its planned cultivation and processing expansion in Florida, for a purchase price of $3,300,000.00. The staged cultivation facility is planned to be a 63,000 square foot building for indoor cultivation, estimated to annually produce 12,000 pounds of premium flower, 2,400 pounds of premium small flower buds, and 6,000 pounds of trim at our 23-acre parcel. The staged cultivation facility is a modular facility designed similarly to the specifications of Planet 13's existing premium California's cultivation facility. Until that building is completed, Planet 13 will continue to use the existing 10,500 square foot building for cultivation and processing activities in Florida.

06:38 EDT Codiak enters partnership with Coalition for Epidemic Preparedness Innovations - CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences announced the latest funding award under CEPI's $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other Betacoronaviruses. CEPI will provide seed funding of up to US $2.5 million to Codiak BioSciences-a clinical-stage biopharmaceutical company based in Cambridge, MA, USA-to continue the advancement of vaccine candidates from its pan Betacoronavirus program through preclinical studies. Codiak's proprietary exoVACC platform leverages engineered exosomes-naturally occurring, extracellular nanoparticle vesicles-to precisely control antigen display on the surface or in the lumen, in order to deliver antigens, adjuvants and immunomodulators selectively to antigen-presenting cells to maximize immune response. Codiak's pan Betacoronavirus vaccine construct carries the receptor-binding domain protein of both SARS-CoV-1 and SARS-CoV-2 at high density on the surface of the exosome, combined with structurally constrained, highly conserved T-cell antigens expressed in the lumen, and stable loading of a STING agonist. This design closely resembles the natural viral structures, and these engineered exosomes stimulate a broad immune response comprising both antibody and T-cell-mediated immunity. Codiak has previously presented preclinical data showing its vaccine candidate stimulates a comprehensive and durable immune response against multiple SARS-CoV-2 variants and the ability to produce antigen-specific T-cell responses against known coronavirus variants of concern. CEPI's funding will enable Codiak to further validate its program in preclinical studies, assessing the immune response against known Betacoronaviruses that already pose a significant epidemic or pandemic risk, such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV, and the potential of the immune response to protect against infection and disease caused by these viruses.

06:36 EDT Missouri American Water files request to review rates with the MoPSC - Missouri American Water filed a request with the Missouri Public Service Commission, or MoPSC, to review its water and wastewater rates. The request is driven by nearly $770Min completed or planned investments from January 2021 to May 2023. The MoPSC's review of the company's request is expected to take 11 months. Any new rates approved by the MoPSC are not expected to become effective until mid-2023. Investments in the rate review include the replacement or installation of 280 miles of aging water and wastewater pipelines - about the distance from St. Louis to Joplin - to help reduce main breaks and sewer overflows. Improvement projects also include the upgrading of treatment plants, storage tanks, wells, pumping and lift stations, fire hydrants, meters and more. If the request is approved by regulators as proposed, the bill for a typical volumetric water customer using an average of 4,200 gallons monthly would increase about $12 or $13 per month. The bill for a typical volumetric wastewater customer would stay about the same, and the bill for flat rate wastewater customers would increase by $3 to $10 per month, depending on the service area. Current bills include an adjustment for the Water and Sewer Infrastructure Act to help pay for certain completed improvement projects. Under the rate review process, these projects are reviewed and may be included in any new rates set by the MoPSC.

06:33 EDT American Water files application for new rates for 2024 through 2026 - California American Water has filed an application to set new rates in each of its service areas for 2024 through 2026. The new rates would take effect January 1, 2024, pending approval by the California Public Utilities Commission. The application includes infrastructure renewals, wildfire mitigation, climate resiliency efforts and strengthening affordability programs. The application seeks a request from California American Water for $462M for infrastructure improvements and investment between 2023-25. The request provides funding to renew and replace water treatment facilities, pumps, and pipelines in our systems around the state. This application is seeking to raise revenue by approximately $95M over three years, beginning with a $56M increase proposed for January 1, 2024. This increase is based on 2024 authorized revenues calculated at current rates. The average impact to customer bills on January 1, 2024 will be between approximately $2.45 and $7.87 per month, depending on region. Specific increases for each service area vary and are detailed in the filing. The increased rates proposed in the rate petition are a request only. The CPUC will make the final decision regarding the actual increase. This process will include extensive independent review and public evidentiary hearings. The process is expected to conclude in late 2023, with new rates taking effect by January 1, 2024.

06:24 EDT AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager - AstraZeneca announced an agreement to acquire TeneoTwo, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. AstraZeneca will acquire all outstanding equity of TeneoTwo in exchange for an upfront payment of $100M on deal closing. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to $805M and additional contingent commercial-related milestone payments of up to $360M to TeneoTwo's equity holders. Overall, the transaction will be accounted for as an intangible asset acquisition, recognized initially at the present value of non-contingent consideration, with future milestones capitalized into the intangible asset as they are recognized. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances. The transaction does not impact AstraZeneca's financial guidance for 2022. "The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. Building on the success of Calquence, TNB-486 further diversifies AstraZeneca's haematology pipeline that spans multiple therapeutic modalities and mechanisms to address a broad spectrum of blood cancers. TNB-486 belongs to a class of therapeutic antibodies known as T-cell engagers, which are emerging as a promising therapeutic approach in haematologic malignancies and solid tumours," the company said.

06:13 EDT ISS recommends Healthcare Realty Trust shareholders to vote "FOR" - Healthcare Realty Trust announced that independent proxy advisory firm Institutional Shareholder Services, or ISS, recommends that Healthcare Realty shareholders vote "FOR" the previously announced transaction with Healthcare Trust of America, at the Company's upcoming special meeting of shareholders scheduled for July 15. The transaction is expected to close on or around July 20, subject to customary closing conditions, including the approval of both Healthcare Realty and Healthcare Trust of America shareholders. Citigroup Global Markets is serving as lead financial advisor, Scotiabank is serving as financial advisor, and Hunton Andrews Kurth is acting as legal advisor to Healthcare Realty. J.P. Morgan Securities is acting as exclusive financial advisor and McDermott Will & Emery LLP is acting as legal advisor to Healthcare Trust of America.

06:10 EDT Armada Hoffler completes $24M retail sale at 4% exit cap rate - Armada Hoffler announced that the Company closed on the disposition of two single-tenant assets leased to Costco and Home Depot, located in Durham, North Carolina for $24 million. The transaction was completed on June 29, 2022. The 4.0% exit capitalization rate represents a substantial improvement over the 4.5% goal shared by the Company during its Q1 2022 Earnings Conference Call on May 3, 2022. The Company had previously announced its intent to sell up to $200 million of noncore assets that were expected to yield premium prices in the current market environment before the end of the year.

06:09 EDT Healthcare Trust reports highest levels of new leases - Healthcare Trust signed its highest level of new leases, approximately 283,000 square feet, since going public in 2012. The company also signed approximately 550,000 square feet of renewal leases. As a result of HTA's performance, total portfolio leased rate increased by 0.3% since Q1 and the company ended the period at 89.6%.

06:07 EDT New Fortress Energy announces agreeement in Mexico with the CFE - New Fortress Energy (NFE) announced that it has entered into an agreement with Comision Federal de Electricidad, or CFE, as part of a growing strategic alliance supported by His Excellency Andres Manuel Lopez Obrador, the President of Mexico, and by Manuel Bartlett, the CEO of CFE. The agreement involves expanding and extending NFE's supply of natural gas to multiple CFE power generation facilities in Baja California Sur, selling NFE's 135 MW La Paz power plant to CFE, and creating a new LNG hub off the coast of Altamira, Tamaulipas, with CFE supplying the requisite feedgas to two NFE FLNG units using CFE's existing pipeline capacity. The transactions are subject to customary terms and conditions and finalization of related agreements.

06:05 EDT New Fortress Energy and Apollo form a new joint venture in a $2B transaction - New Fortress Energy (NFE) and Apollo (APO) announced that they have entered into a definitive Equity Purchase and Contribution Agreement to sell 11 LNG infrastructure vessels owned by NFE to a newly formed joint venture between funds managed by Apollo and NFE in a transaction valued at approximately $2B. The JV will be owned approximately 80% by Apollo funds and 20% by NFE. This transaction will create a global marine infrastructure platform underpinned by long-term contracts, benefitting from NFE's LNG downstream operations and development activities, as well as Apollo's leading investment and maritime experience. The 11-vessel portfolio consists of 6 Floating Storage and Regasification Units, 2 LNG Carriers, and 3 Floating Storage Units. The total implied enterprise value of the transaction is approximately $2B and NFE will receive approximately $1.1B in proceeds after accounting for NFE's share of the JV and paydown of existing debt. As part of the transaction, NFE has agreed to charter 10 of the 11 of the vessels from the Platform for a period of up to 20 years commencing either upon close of the transaction or upon expiration of the vessels' existing third-party charter agreements. Subject to satisfying customary closing conditions, including receipt of certain regulatory approvals and third-party consents, closing of the transaction is expected to occur in Q3. Transaction proceeds are expected to be utilized to fund NFE's FLNG projects, as well as for ongoing downstream infrastructure and general corporate purposes.

05:18 EDT Fluence Energy announces strategic partnership with Rich Electric - Fluence Energy announced a strategic partnership with Rich Electric, a Taiwanese company with expertise in power conversion and battery-based energy storage systems. Through this partnership, Fluence and Rich Electric will deploy a 100 MW battery-based energy storage system in Hualien to support Taipower's automatic frequency control, or AFC, services. With a target completion of mid-2023, the project will be the first 100 MW level system in Taiwan, and is anticipated to be one of Fluence's largest AFC projects in the country.

05:13 EDT AST SpaceMobile to sell majority ownership stake in NanoAvionics for $68M - AST SpaceMobile announced it has entered into a definitive agreement to sell its majority ownership stake in NanoAvionics, a smallsat mission integrator and bus manufacturer based in Lithuania. The transaction values NanoAvionics at an enterprise valuation of approximately $68M and is expected to close in the third quarter of 2022, subject to customary closing conditions including any required regulatory reviews, and generate approximately $28M in net proceeds to AST SpaceMobile at closing. AST SpaceMobile will sell its majority stake NanoAvionics to Kongsberg Defence & Aerospace, the Nordic region's largest industrial space company and global leader in maritime surveillance.

05:09 EDT InterDigital signs multi-year royalty bearing license with Zebra Technologies - InterDigital (IDCC) announced that it has signed a multi-year, worldwide, non-exclusive, royalty bearing license with Zebra Technologies (ZBRA) under InterDigital's standard essential patents related to 4G and 5G wireless, and WiFi technology.

05:05 EDT Natuzzi shareholders approve new stock option plan - Natuzzi announced that the Company's shareholders have approved a new stock option plan for the group's personnel and all related documents at an extraordinary shareholders' meeting of the company held on July 1 and have authorized the company's board of directors to carry out, in one or more tranches, the capital increase without preemptive rights that will be necessary to issue ordinary shares of the company to employees under the plan.